CompletedNCT00226317
Aripiprazole for acute depression and longer-term mood stability in bipolarity
About this title
Aripiprazole in the Treatment of Bipolar Depression
Read the official source — NCT00226317Medication studyAges 18–64United States
Understand this study
Who was this study for?
Listed age limits: 18 years to 64 years.
What did participation involve?
The study group receives aripiprazole as a study medication.
- Listed locations
- CambridgeSee all locations and recruitment
Study information
Study start dateApril 2004
- Recruitment status
- Completed
- Enrollment listed in the registry
- 20
- Sponsor
- Cambridge Health Alliance
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Not clearly listed
- Locations
- United States
- Age range
- From 18 Years to 64 Years
- Official registry ID
- NCT00226317
- Official title
Show the full official title
Phase 4 Study: An Open Prospective Study of the Safety and Effectiveness of Aripiprazole in the Treatment of Bipolar Depression
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Cambridge
Questions about this study
Who is behind this study?
The study sponsor is Cambridge Health Alliance.
Did this study involve medication?
Yes. The study involved medication, including Aripiprazole.
Who was this study for?
Listed age limits: 18 years to 64 years.
